Related Experiment Video
Updated: Jul 7, 2026

05:18
Radiation Planning Assistant - A Web-based Tool to Support High-quality Radiotherapy in Clinics with Limited Resources
Published on: October 6, 2023
Current status of accelerated partial breast irradiation.
Michihide Mitsumori1, Masahiro Hiraoka
1Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine Kyoto University, Kyoto 606-8507, Japan. mitsumo@kuhp.kyoto-u.ac.jp
Breast Cancer (Tokyo, Japan)
|January 29, 2008
Summary
Accelerated partial breast irradiation (APBI) offers a shorter radiotherapy course for breast cancer patients. While promising, its long-term effectiveness and safety compared to whole breast irradiation require further study, especially for smaller breast sizes.
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Accelerated partial breast irradiation (APBI) is a radiotherapy technique for breast-conserving therapy.
- It targets the tumor bed post-surgery, hypothesizing that most recurrences are local.
- APBI aims to reduce treatment time and cost compared to whole breast irradiation.
Purpose of the Study:
- To review the current status and challenges of APBI.
- To assess its potential benefits and limitations in breast cancer treatment.
Main Methods:
- Review of existing APBI techniques: multicatheter interstitial brachytherapy, intracavitary brachytherapy, intraoperative radiation therapy, and 3D conformal external beam radiation therapy.
- Analysis of current clinical adoption and research findings.
Main Results:
- APBI is increasingly adopted in the US and Europe with promising short-term outcomes.
- Techniques vary, each with distinct advantages and disadvantages.
- Equivalence to whole breast radiation therapy is not yet fully established.
- Application in Japanese patients presents unique technical challenges due to smaller average breast size.
Conclusions:
- APBI shows potential for efficient breast cancer treatment but requires further validation.
- Long-term efficacy and safety need clarification through ongoing clinical trials.
- Optimizing APBI delivery methods for diverse patient populations, including those in Japan, is crucial.

